CardiaLen develops and commercializes pain-free cardioversion therapies for atrial fibrillation.
CardiaLen develops and commercializes pain-free cardioversion therapies for atrial fibrillation. The company is developing implantable low-energy (low voltage) pain-free atrial cardioverters to help address the major unmet needs of this condition.It was founded in 2008 and headquartered in Minneapolis, Minnesota.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 19, 2021 | Grant | $2.80M | 1 | National Institutes of Health | — | Detail |
Mar 26, 2015 | Series B | $1.52M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Institutes of Health | Yes | Grant |
Twin Cities Angels | — | Series B |